These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1279324)
1. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Lee EJ; Yang J; Leavitt RD; Testa JR; Civin CI; Forrest A; Schiffer CA Leukemia; 1992 Nov; 6(11):1203-9. PubMed ID: 1279324 [TBL] [Abstract][Full Text] [Related]
3. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393 [TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Del Poeta G; Venditti A; Stasi R; Aronica G; Cox MC; Buccisano F; Tamburini A; Bruno A; Maurillo L; Battaglia A; Suppo G; Epiceno AM; Del Moro B; Masi M; Amadori S; Papa G Leuk Res; 1999 May; 23(5):451-65. PubMed ID: 10374859 [TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Chang H; Salma F; Yi QL; Patterson B; Brien B; Minden MD Leuk Res; 2004 Jan; 28(1):43-8. PubMed ID: 14630079 [TBL] [Abstract][Full Text] [Related]
8. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688 [TBL] [Abstract][Full Text] [Related]
9. Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia. Schachner J; Kantarjian H; Dalton W; McCredie K; Keating M; Freireich EJ Leukemia; 1988 Oct; 2(10):667-71. PubMed ID: 3172842 [TBL] [Abstract][Full Text] [Related]
10. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696 [TBL] [Abstract][Full Text] [Related]
11. Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. Paietta E; Neuberg D; Bennett JM; Dewald G; Rowe JM; Cassileth PA; Cripe L; Tallman MS; Wiernik PH; Leukemia; 2003 Aug; 17(8):1544-50. PubMed ID: 12886241 [TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651 [TBL] [Abstract][Full Text] [Related]
13. CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Ciolli S; Leoni F; Caporale R; Pascarella A; Salti F; Rossi-Ferrini P Haematologica; 1993; 78(3):151-5. PubMed ID: 7690733 [TBL] [Abstract][Full Text] [Related]
14. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095 [TBL] [Abstract][Full Text] [Related]
15. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Sperling C; Büchner T; Creutzig U; Ritter J; Harbott J; Fonatsch C; Sauerland C; Mielcarek M; Maschmeyer G; Löffler H Leuk Lymphoma; 1995 May; 17(5-6):417-26. PubMed ID: 7549832 [TBL] [Abstract][Full Text] [Related]
16. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes]. Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638 [TBL] [Abstract][Full Text] [Related]
18. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203 [TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Willman CL Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958 [TBL] [Abstract][Full Text] [Related]
20. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. Schaich M; Illmer T; Seitz G; Mohr B; Schäkel U; Beck JF; Ehninger G Haematologica; 2001 May; 86(5):470-7. PubMed ID: 11410409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]